01 / MULTILINGUAL EVIDENCE↗
Language carries nuance.
Arabic, English and mixed clinical narratives require context-aware extraction and reviewer confirmation — not blind keyword matching.
ARABIC + ENGLISH · EXPERT-LED REVIEW01 / BIO-CLINICAL OVERVIEW
AI-ASSISTED PHARMACOVIGILANCE
Every signalhas a story.Follow theevidence.كل إشارةتحمل قصة.تتبّع الأدلة.
A connected workspace for drug-safety teams. Investigate Arabic and English reports, explore signals and document expert review with traceable evidence.
∿THE EVIDENCE FIELD
AN INTERPRETIVE VISUAL
AN INTERPRETIVE VISUAL
FORM / TRACE / QUESTION / REVIEW
DRAG TO ORBIT / PINCH OR ZOOM / EXPLORE THE SIGNAL
OBSERVATION FIELD
02 / INSIDE THE WORKBENCH · REFERENCE BETA
See the investigation.
Not just the promise.
Follow an investigation through intake, signal review, biological context and expert assessment. These reference captures show the workflow using demonstration data.
REFERENCE CAPTURE · NO LIVE PATIENT DATA
STAGE 01 · BILINGUAL INTAKE & PHI QUARANTINESOURCE OBSERVATION ≠ CAUSAL PROOF
01 / BILINGUAL CLINICAL INTAKE
Read the report. Preserve the context.
Review candidate drugs and events against the original Arabic or English narrative. Confirm context, negation and terminology before moving into investigation.
EVIDENCE TO REVIEW: Source text · Entity spans · Assertion and timing · Terminology decisions
REFERENCE CAPTURES · SWITCH STAGES TO EXPLORE
01 / DEMONSTRATED
See how the pieces connect.
Four reference captures connect the original report, signal context, supporting evidence and the reviewer’s assessment.
02 / SCIENTIFIC BOUNDARY
Evaluate the evidence.
The Beta illustrates the workflow. Model performance, security controls and deployment readiness need scope-specific validation; no regulatory approval is implied.
03 / NEXT STEP
Discuss your evaluation.
Discuss your reporting languages, data sources, review process and deployment requirements.
DISCUSS YOUR USE CASE ↗REFERENCE CAPTURES · NO LIVE PATIENT DATA · REQUEST A GUIDED WALKTHROUGH ↗
03 / WHY NAWAOUR POINT OF VIEW
NOT EVERY PATTERN IS A CAUSE.
NOT EVERY QUESTION HAS AN EASY ANSWER.
An observation
is only the
beginning.
A case narrative, a statistical signal and a biological explanation often live in separate tools. NAWA brings them into one investigation, with the source and the reviewer’s reasoning in view.
DISCOVER OUR APPROACH ↗04 / BIO-CLINICAL CONVERGENCE ENGINEONE EVIDENCE JOURNEY · FOUR DISTINCT QUESTIONS
NAWA I-VIG / THE INVESTIGATION PROCESS
From observation
to accountable review.
Language, signals and molecular context don't prove a cause. They form a structured path to questions qualified experts can investigate and sign off.
01 / CLINICAL LANGUAGE
First, listen precisely.
Read Arabic and English reports in context. Review drugs, events and negation against the original words.
RCSB STRUCTURE 2F9Q ↗SCIENTIFIC BOUNDARYAn observation is not a causal conclusion.
CLINICAL NLP / ASSERTION & NEGATION
01 / SEMANTIC STRANDSCONCEPTUAL · NOT PATIENT DATA
BILINGUAL / ASSERTION / NEGATION
05 / SIX LAYERS OF TRACEABLE EVIDENCEAN ANATOMY OF ACCOUNTABILITY
EVIDENCE CHAIN OF CUSTODY
Every assessment
needs a trail.
Follow the source, method, biological context, timing, prioritization and human review behind an assessment.
R1 / 06INSPECT THE EVIDENCE LAYER ↗
Provenance, before interpretation.
Trace a finding back to its source identity, transformation history and versioned context. Knowing where evidence came from is the first step to understanding what it can support.
INTEGRITY ≠ MEDICAL CORRECTNESS
INTERACTIVE CONCEPT / NO LIVE CASE OR CLINICAL DATA SHOWN
06 / PRIMARY SCIENTIFIC FOUNDATIONSREAL QUESTIONS. TRACEABLE METHODS.
A CONNECTED RESEARCH WORKSPACE
Go deeper.
Stay grounded.
NAWA connects the questions that traditional workflows can leave scattered — while keeping a sharp distinction between a computational result, evidence and a human decision.
02 / TEMPORAL INTELLIGENCE↗
Time is evidence, too.
Investigate timing, persistence and reporting changes without turning spontaneous reports into incidence or causal estimates.
03 / MECHANISTIC INVESTIGATION↗
Explore what might connect.
Mechanistic evidence can challenge a hypothesis, surface contradictions and reveal gaps. Plausibility never substitutes for causal proof.
OUR SCIENTIFIC PRINCIPLE
Powerful tools.
Humble conclusions.
Because trust is built by showing what you know — and what you don't.
07 / TRUST & GOVERNANCERESEARCH / PRODUCT / GOVERNANCE
THE NAWA PRINCIPLES
Built to earn
the right to
be trusted.
Clear sources. Explicit uncertainty. Accountable reviewers. Evaluation should establish which capabilities and controls are qualified for your intended use.
01↗
Humans make the call.
Structured review, rationale and approvals remain with accountable experts.
02↗
Follow the source.
Source identity and evidence lineage travel with the investigation, not as an afterthought.
03↗
Respect the boundary.
Signals, hypotheses, causal estimates and regulatory decisions are different kinds of claims.
04↗
Keep control close.
Customer-governed deployment is a design priority. Security, data flows and operating controls are assessed for each evaluation scope.
WHO WE ARE BUILDING FOR
Better questions.
Better collaboration.
01 — PHARMACEUTICAL SAFETY
PV & safety teams
Move between safety cases, emerging patterns and reviewable evidence.
02 — SCIENTIFIC RESEARCH
Medical & research teams
Explore mechanisms, uncertainty and the provenance of scientific claims.
03 — GOVERNANCE
Quality & oversight
Inspect decisions, supporting records and human accountability.
08 / DEMO · TECHNICAL DILIGENCE · PARTNERSHIPSTHE NEXT QUESTION IS YOURS
NAWA I-VIG / SCIENTIFIC PHARMACOVIGILANCE
Let’s investigate
what matters to you.
CHOOSE THE CONVERSATION
Evidence-led pharmacovigilance, with human judgement at the center. Prefer a direct conversation?
contact@nowaivik.com